Supernus Deal History & Licensing Activity
Supernus is a biotech headquartered in Israel. Over the past three years, Supernus has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals). The company currently has 10 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
3
Active Trials
10
Top Modality
Small Molecules
Focus Area
CNS Disorders
Supernus Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Supernus in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| neuroscience portfolio | Sage Therapeutics | Small Molecules | Approved | acquisition | Jun 2025 |
Supernus Pipeline Focus
Therapeutic areas and modalities where Supernus is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Supernus Strategic Signals
Key indicators of Supernus's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Supernus Clinical Pipeline
Supernus has 10 active clinical trials across 5 development phases.
2
Unknown
1
Phase 4
1
Phase 1
4
Phase 2
2
Phase 3
See How Your Asset Matches Supernus's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Supernus Licensing & Deal Activity
Supernus is a biotech company based in Israel that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Supernus ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Supernus include CNS Disorders (6 deals and trials), and Neurology (2 deals and trials). In terms of modality, Supernus has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Supernus and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Supernus's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.